OTC:ONPPF Oncopeptides AB (publ) (ONPPF) Stock Price, News & Analysis → Democrats’ “break glass for emergency” candidate for 2024 (From The Freeport Society) (Ad) Free ONPPF Stock Alerts $0.26 0.00 (0.00%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$0.27▼$0.2750-Day Range$0.27▼$0.6052-Week Range$0.27▼$0.27VolumeN/AAverage Volume2,250 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartStock AnalysisAnalyst ForecastsChart Get Oncopeptides AB (publ) alerts: Email Address Ad The Freeport SocietyDemocrats’ “break glass for emergency” candidate for 2024Nate Silver has been a celebrity pundit since at least the 2008 election, when he correctly predicted the winner in 49 of 50 states, and nailed all 35 Senate election outcomes. But interestingly, one man reached the same conclusion as Nate Silver a long time ago…For full details, click here. About Oncopeptides AB (publ)Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, SwedenRead More ONPPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONPPF Stock News HeadlinesMarch 6, 2024 | gurufocus.comOncopeptides AB (publ) - Special Call TranscriptMarch 6, 2024 | gurufocus.comOncopeptides AB (publ) To Present Updated Ocean Results Call TranscriptNovember 25, 2022 | prnewswire.comOncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment BankNovember 11, 2022 | finance.yahoo.comOncopeptides' Pepaxti has been granted marketing authorization in the UKNovember 9, 2022 | finance.yahoo.comOncopeptides announces the market potential for Pepaxti in EuropeNovember 9, 2022 | finance.yahoo.comOncopeptides publishes Q3 report 2022October 26, 2022 | finance.yahoo.comOncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufenOctober 20, 2022 | finance.yahoo.comIssue and re-purchase of class C shares for shareholder program and incentive programOctober 5, 2022 | finanznachrichten.deOncopeptides AB: Oncopeptides starts commercialization of Pepaxti in Europe - Germany first marketOctober 3, 2022 | finance.yahoo.comOncopeptides starts commercialization of Pepaxti in Europe - Germany first marketSeptember 23, 2022 | finance.yahoo.comSwedish Biotech’s Cancer Drug Fails With FDA AdvisersSeptember 23, 2022 | finance.yahoo.comOncopeptides provides an update from the meeting with FDAs advisory committee ODACSeptember 23, 2022 | finance.yahoo.comBulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ)September 20, 2022 | finance.yahoo.comBriefing Book for ODAC meeting on benefit/risk profile of Pepaxto now publishedSeptember 19, 2022 | reuters.comONCO.ST - Oncopeptides AB | Stock Price & Latest News | ReutersSeptember 7, 2022 | finance.yahoo.comOncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myelomaAugust 18, 2022 | finance.yahoo.comEuropean Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myelomaAugust 13, 2022 | seekingalpha.comOncopeptides AB GAAP EPS of -SEK0.79, revenue of SEK8.8MAugust 11, 2022 | finance.yahoo.comOncopeptides publishes Q2 report 2022February 17, 2022 | finance.yahoo.comOncopeptides publishes year-end report 2021February 14, 2022 | finance.yahoo.comInvitation to presentation of 2021 year-end resultsJanuary 21, 2022 | finance.yahoo.comOncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this timeJanuary 13, 2022 | finance.yahoo.comOncopeptides phase 3 OCEAN study published in the Lancet HaematologyJanuary 5, 2022 | prnewswire.comOncopeptides announces year-end cash 2021December 10, 2021 | finance.yahoo.comOncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASHSee More Headlines Receive ONPPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncopeptides AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTC SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTC:ONPPF CUSIPN/A CIKN/A Webwww.oncopeptides.se Phone46 86 15 20 40FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesProf. Rolf Larsson M.D.Ph.D., FounderProf. Rolf Lewensohn M.D.Ph.D., FounderDr. Joachim Gullbo M.D.MSc Pharm, Ph.D., FounderDr. Kristina Luthman Ph.D.FounderProf. Hans Ehrsson M.D.FounderMr. Peter Nygren (Age 65)Founder Mr. Henrik Bergentoft (Age 50)Chief Financial Officer Ms. Eva Nordström M.Sc. (Age 54)MSc Pharm, COO & Deputy MD Ms. Sara Svardgren (Age 45)Head of Human Resources Mr. Rein Piir B.Sc. (Age 66)Senior Advisor More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors ONPPF Stock Analysis - Frequently Asked Questions Should I buy or sell Oncopeptides AB (publ) stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncopeptides AB (publ) in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ONPPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONPPF, but not buy additional shares or sell existing shares. View ONPPF analyst ratings or view top-rated stocks. How have ONPPF shares performed in 2024? Oncopeptides AB (publ)'s stock was trading at $0.60 at the beginning of 2024. Since then, ONPPF stock has decreased by 55.8% and is now trading at $0.2650. View the best growth stocks for 2024 here. How do I buy shares of Oncopeptides AB (publ)? Shares of ONPPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTC:ONPPF) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredMy 3 Top CryptocurrenciesMore than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncopeptides AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncopeptides AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.